Abstract
Esaxerenone, a mineralocorticoid receptor blocker (MRB), is a new antihypertensive agent. However, esaxerenone-related data with respect to hypertension with heart failure are limited. We investigated the safety and efficacy of esaxerenone in hypertensive patients with heart failure with reduced ejection fraction (HFrEF). Hypertensive patients with HFrEF treated with esaxerenone were retrospectively analyzed at two timepoints (short-term: 35±15 days; mid-term: 167±45 days). Adverse events including hyperkalemia (K+ >5.5 mEq/L), worsening renal function (WRF; estimated glomerular filtration rate (eGFR) reduction by ≥20%), and hypotension (systolic blood pressure <90 mmHg) were evaluated. eGFR and K+, serum creatinine, and brain natriuretic peptide (BNP) levels at baseline, short-term, and mid-term assessments were compared. Patients administered esaxerenone as their first MRB (first-MRB cohort) and those who converted from another MRB (conversion cohort) were separately analyzed. There were 50 (56±10 years old, 26% female) patients. At the short-term assessment, hyperkalemia or hypotension was not observed at a dose of 2.0±0.9 mg/day. Seven patients (14%) showed WRF. K+ was slightly elevated (4.12±0.41 to 4.25±0.39 mmol/L, p = 0.07) and eGFR was significantly reduced (66.9±19.6 mL/min/1.73 m2 to 62.4±19.7 mL/min/1.73 m2, p = 0.006). In the conversion cohort, significant changes in K+ and eGFR from baseline were not observed at the short-term assessment. BNP levels were consistently improved regardless of the cohorts (first-MRB cohort, 310 [110-370] pg/mL to 137 [47-152] pg/mL, p = 0.001; conversion cohort, 181 [30-203] pg/mL to 108 [26-146] pg/mL, p = 0.028). At the mid-term assessment, there were no significant changes in K+ and eGFR compared with the short-term assessment. In conclusion, esaxerenone was safe for hypertensive patients with HFrEF. Hyperkalemia and hypotension were rarely noted, while eGFR was marginally reduced. Moreover, esaxerenone might be beneficial for HFrEF in terms of BNP level reduction.
Highlights
Hypertension is a major risk factor for heart failure (HF) [1]
In patients with Mineralocorticoid receptor (MR)-associated hypertension, MR blockers (MRBs) with first-line antihypertensive agents, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics have been suggested to be effective in controlling blood pressure (BP) [3]
Patients in the finerenone group showed a significant decrease of kidney disease progression or cardiovascular death compared to the placebo group, suggesting that MRBs improve both the renal and cardiovascular prognosis in patients with diabetic nephropathy [9]
Summary
Hypertension is a major risk factor for heart failure (HF) [1]. Mineralocorticoid receptor (MR)-associated hypertension, in which MR is excessively stimulated, is detected in a proportion of patients presenting with resistant hypertension [2]. In patients with MR-associated hypertension, MR blockers (MRBs) with first-line antihypertensive agents, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics have been suggested to be effective in controlling blood pressure (BP) [3]. The FIDELIO-DKD trial investigating the kidney and cardiovascular outcomes and safety of finerenone, a novel non-steroidal MRB, compared with a placebo in patients with type 2 diabetes and chronic kidney disease with albuminuria was published [9]. Patients in the finerenone group showed a significant decrease of kidney disease progression or cardiovascular death compared to the placebo group, suggesting that MRBs improve both the renal and cardiovascular prognosis in patients with diabetic nephropathy [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
